Datuk Dr.Doris Wong Sing Ee

Form D signer

Datuk Dr.Doris Wong Sing Ee

Chief Executive Officer at Cyclacel Pharmaceuticals

Form D signer

Capital raised by Cyclacel Pharmaceuticals

$1.0M+$1.0M latest round

3 Form D filings · first filed Feb 2025 · Berkeley Heights, NJ

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 3
TEAM ON FILE: 4
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

Cyclacel PharmaceuticalsBiotech · Berkeley Heights, NJsince Feb 2025

Chief Executive Officer

Signatory on Cyclacel Pharmaceuticals's Form D filings · $1.0M raised across 3

Company filings

via EDGAR · Form D for Cyclacel Pharmaceuticals3

DateCompanyFormAmountRole on filing

Mar 21, 2025Cyclacel PharmaceuticalsForm D+$1.0MChief Executive Officer

Form DMar 21, 2025 · Cyclacel Pharmaceuticals+$1.0Mas Chief Executive Officer

Feb 14, 2025Cyclacel PharmaceuticalsForm D—Chief Executive Officer

Form DFeb 14, 2025 · Cyclacel Pharmaceuticals—as Chief Executive Officer

Feb 6, 2025Cyclacel PharmaceuticalsForm D—Chief Executive Officer

Form DFeb 6, 2025 · Cyclacel Pharmaceuticals—as Chief Executive Officer

Overview

Last filing Mar 21, 2025

Datuk Dr.Doris Wong Sing Ee is on file as Chief Executive Officer at Cyclacel Pharmaceuticals in Berkeley Heights, NJ. Cyclacel Pharmaceuticals has 3 Form D filings on record, $1.0M raised in total. Datuk Dr.Doris Wong Sing Ee appears as a signatory on the company's filings.

Teammates

Cyclacel Pharmaceuticals · 3

Avraham Ben-TzviDirector David LazarInterim Chief Executive OfficerSigner Samuel BarkerDirector

Products

Cyclacel Pharmaceuticals · 1

Novel Oncology TreatmentsOncology

Cyclacel Pharmaceuticals develops a range of therapeutic candidates aimed at overcoming cancer drug resistance utilizing targeted approaches in cell cycle biology, transcriptional regulation, and mitosis biology. These innovative treatments are designed to tackle cancers that have proven challenging for conventional therapies.